AstraZeneca HK, Lippo Healthcare partner for health innovation in GBA

The collaboration will address healthcare challenges in treating chronic diseases.

AstraZeneca Hong Kong and Lippo Healthcare (HK) Limited have signed a memorandum of understanding to invest in and develop health innovation in the Greater Bay Area (GBA).

This will promote collaboration of Hong Kong-Shenzhen and other cities in the GBA, enhancing access to healthcare. It will particularly provide solutions for chronic diseases, such as cardiovascular, respiratory and oncology.

“AstraZeneca Hong Kong formulates the strategic direction in the GBA with a staunch commitment to bring patients a better medical solution,” Gwenael Meneux, General Manager of AstraZeneca Hong Kong & Macau, said in a statement.

“The cooperation with Lippo Healthcare is essential for us to deliver innovative healthcare solution to address the challenges in the GBA.”

The initiative will be supported by the AstraZena China Healthcare IoT Innovation Centre and its connection with innovative platforms in Hong Kong.

It was noted that not only will it develop solutions for healthcare challenges, the AstraZeneca HK-Lippo Healthcare collaboration is also expected to reinforce Hong Kong’s status as a key accelerator of innovation in the GBA.